Pfizer: A Dose of Defense in a Feel-Good Market

As the market has rallied to record levels in recent weeks, Pfizer has enjoyed the ride, and then some. The pharmaceutical giant is up about 12% compared with 9% for the Standard & Poor’s 500.

Yet unlike many other stocks trading at 52-week highs (or better), the drug maker can still be had for less than 12 times forward earnings, and its robust 3.4% payout looks likely to grow.


Continue Reading